Home
Healthcare
Healthcare & Pharmaceuticals
Radiation Injury Drugs Market Share & Growth | Forecast 2031

Global Radiation Injury Drugs Market

Name: Growth Market Reports
Address: 500 East E Street, Ontario, 91764, USA
Telephone: +1 909 414 1393

Segments - by Exposure (Internal Exposure and External Exposure), Source (Background Radiation and Man-Made Radiation), Diagnosis (Lymphocytes Count, Geiger-Muller Counter, and Blood Test And Dosimeter), Treatment (Treatment For Radiation Sickness, Treatment For Internal Contamination, and Others), Route Of Administration (Oral and Parenteral), Application (Ambulatory Surgery Centers (ASCs), Hospitals, Research Institutes, and Others), and Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA)) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

HC-2723
4.5 Rating
299 Pages

12-11-2021
72 Reviews

Author :

Raksha Sharma

Fact-checked by :

Vineet Pandey

Editor :

Vishal Golekar

Report Description

Radiation Injury Drugs Market Outlook

The global radiation injury drugs Market was valued at USD 565.6 million in 2020 and is projected to reach USD 747.9 million by 2028, expanding at a CAGR of 3.7% during the forecast period. Radiation injury is responsible for causing damage to tissues, due to the exposure of ionizing radiation. High dose of ionizing radiation causes acute illness through the reduction in the production of blood cells and damages the digestive tract. Sources of ionizing radiation are natural such as radioactive substances or man-made such as X-ray machines, particle accelerators, nuclear reactors, and nuclear weapons. Tissue damage by radiation therapy leads to skin necrosis, dermatitis, and ulcer. Above 70% of patients experience radiodermatitis, which ranges from dry desquamation, faint erythema, moist desquamation, and necrosis, during the course of radiotherapy.

Systemic radiation therapy uses radioactive drugs known as radionuclides or radiopharmaceuticals for the treatment of certain types of cancer such as thyroid, bone, and prostate cancer. These drugs are made up of a radioactive substance. They are mainly given by mouth or put into a vein, and then travel throughout the body. Radiation injury drugs are used in the detection of cancer, during bone metastasis when cancer spreads to the bone. These drugs are used to diagnose other non-cancer health problems.

Radiation Injury Drugs Market Dynamics

Rising prevalence of cancer patients globally, as well as their preference for radiation therapy, are driving the radiation injury drugs market. According to the International Agency for Research on Cancer, 19.3 million cancer cases and 10 million cancer deaths are expected to occur globally in 2020.

Expansion of the radiation injury medicine market is anticipated to be fueled by an increase in cancer patients. Increased reimbursement policies for radiation therapy and associated treatment for side effects are expected to fuel the radiation injury drugs market.

The day-to-day components of the RO-APM are controlled by a mix of clinicians, the nursing team, radiation therapists, as well as billing and administration employees at the clinical sharp-end. Participating care providers will get all-inclusive reimbursement (rather than fee-for-service), indicating that workflow efficiency will become a defining credo – and the only way for clinics to succeed financially in the long run.

According to the World Cancer Report, cancer has a high incidence rate over the world, with an estimated 20 million cases by 2030. (WHO, 2008). Every year in India, approximately 0.95 million new cancer cases are discovered, with 0.63 million deaths. Breast cancer is frequent among women, and it is the second highest cause of mortality in women. Despite the fact that the prevalence of breast cancer in developing nations is relatively low, industrialized countries diagnose nearly half of all instances of breast cancer.

According to a study conducted between 1975 and 1990, Asia and Africa registered a faster increase in the annual incidence rate of breast cancer than North America and Europe. Increasing number of awareness campaigns about the benefits of radiotherapy and technological developments in radiotherapy devices led to rising use of radiotherapy devices and treatments. The ESTRO Cancer Foundation and ESTRO launched the Marie Curie Legacy Campaign, a global movement, to raise awareness about the benefits of radiotherapy and improve radiotherapy delivery throughout Europe and beyond.

During the projected period, development prospects in emerging markets and rising demand for cancer treatment are expected to present multiple opportunities for market expansion. Radiotherapy, known as radiation therapy, is a treatment for cancer patients that involves eliminating cancer cells and shrinking tumors. Radiation such as X-rays, gamma rays, and charged particles are often employed in radiotherapy.

According to the National Cancer Institute, nearly half of all cancer patients receive radiation therapy as part of their treatment. In the future years, emerging economies such as India, China, Brazil, and Russia are expected to demonstrate tremendous development potential.

India and China are home to more than half of the world's population, and these markets have a huge number of end users in the radiation injury drugs market. This is fuelled by the rising cancer rates in these countries. During the projected period, development prospects in emerging markets and increasing demand for cancer treatment are expected to present several opportunities for market expansion.

Radiation Injury Drugs Market Segmental Outlook

By Exposure

On the basis of exposure, the radiation injury drugs market is segregated into internal exposure and external exposure. The external exposure segment is projected to hold a significant market share during the forecast period.

By Route of Administration

On the basis of route of administration, the radiation injury drugs market is segmented into oral and parenteral. The parenteral segment is expected to account for a significant share of the market in the projected timeline.

By Diagnosis

On the basis of diagnosis, the radiation injury drugs market is divided into lymphocytes count, Geiger-Muller counter, and blood test, and dosimeter. The blood test and dosimeter segment is estimated to constitute a significant share of the market during the forecast period.

By Application

On the basis of applications, the radiation injury drugs market is categorized as ambulatory surgery centers (ASCs), hospitals, research institutes, and others (long-term care centers). High purchasing power of hospitals to buy advanced radiation drugs connectivity solutions, decreasing hospital margins, and growing focus on providing high-quality patient care and safety are key factors that are estimated to drive the hospitals segment growth.

Radiation Injury Drugs Market Region Wise Outlook

Based on regions, the global radiation injury drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to grow at a rapid pace than the market in the rest of the world, owing to the rising number of cancer patients.

As a result, demand for radiotherapy increased in the region, along with healthcare spending. Europe accounts for a significant share of the market, due to growing treatment of radiation injury. For example, cutaneous radiation injury therapy is common in Europe.

Asia Pacific constitutes a significant market share, particularly China, due to growing number of patients and low treatment cost. South Africa is projected to dominate the MEA radiation injury drugs market with a considerable share. The market is growing, due to the frequency of cancer, high mortality rate, and favorable government regulations. Growing geriatric population is driving the Radiation Injury Drugs Market in Latin America. Globally, the geriatric population is rapidly increasing, contributing to an increase in chronic diseases.

Key Benefits for Industry Participants & Stakeholders

In-Depth Analysis of the global radiation injury drugs market.
Historical, Current and Projected Market Size in Terms of Value.
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
Industry Drivers, Restraints and Opportunities Covered in the Study
Recent Industry Trends and Developments
Competitive Landscape & Strategies of Key Players
Neutral Perspective on global radiation injury drugs market performance

Segments

By Exposure

Internal Exposure
External Exposure

By Source

Background Radiation
Man-Made Radiation

By Diagnosis

Lymphocytes Count
Geiger-Muller Counter
Blood Test and Dosimeter

By Treatment

Treatment For Radiation Sickness
Treatment For Internal Contamination
Others

By Route of Administration

Oral
Parenteral

By Application

Ambulatory Surgery Centers (ASCs)
Hospitals
Research Institutes
Others

By Regions

North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)

Key Market Players Profiled in the Report

Eli Lilly and Company
Teva Pharmaceutical
Amgen Inc.
La Jolla Pharmaceutical Co
Novartis
Johnson & Johnson
Heyl Chemisch-pharmazeutische Fabrik

Competitive Landscape

Key players in the global radiation injury drugs market are Eli Lilly and Company, Teva Pharmaceutical, Amgen Inc, La Jolla Pharmaceutical Co, Novartis, Johnson & Johnson, Heyl Chemisch-pharmazeutische Fabrik.
The players are adopting key strategies such as product development, geographical expansion, mergers and acquisition and many other strategies to cater the increasing demand for radiation injury drugs market.

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Radiation Injury Drugs Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Radiation Injury Drugs Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Radiation Injury Drugs Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Radiation Injury Drugs Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Radiation Injury Drugs Market Size & Forecast, 2018-2028
      4.5.1 Radiation Injury Drugs Market Size and Y-o-Y Growth
      4.5.2 Radiation Injury Drugs Market Absolute $ Opportunity
   4.6 Global Radiation Injury Drugs Market: Impact of Key Regulations
   4.7 Global Radiation Injury Drugs Market: Pipeline Analysis
Chapter 5 Global Radiation Injury Drugs Market Analysis and Forecast By Exposure
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Exposure
      5.1.2 Basis Point Share (BPS) Analysis By Exposure
      5.1.3 Absolute $ Opportunity Assessment By Exposure
   5.2 Radiation Injury Drugs Market Size Forecast By Exposure
      5.2.1 Internal Exposure
      5.2.2 External Exposure
   5.3 Market Attractiveness Analysis By Exposure
Chapter 6 Global Radiation Injury Drugs Market Analysis and Forecast By Source
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Source
      6.1.2 Basis Point Share (BPS) Analysis By Source
      6.1.3 Absolute $ Opportunity Assessment By Source
   6.2 Radiation Injury Drugs Market Size Forecast By Source
      6.2.1 Background Radiation
      6.2.2 Man-made Radiation
   6.3 Market Attractiveness Analysis By Source
Chapter 7 Global Radiation Injury Drugs Market Analysis and Forecast By Diagnosis
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Diagnosis
      7.1.2 Basis Point Share (BPS) Analysis By Diagnosis
      7.1.3 Absolute $ Opportunity Assessment By Diagnosis
   7.2 Radiation Injury Drugs Market Size Forecast By Diagnosis
      7.2.1 Lymphocytes Count
      7.2.2 Geiger-Muller Counter
      7.2.3 Blood Test And dosimeter
   7.3 Market Attractiveness Analysis By Diagnosis
Chapter 8 Global Radiation Injury Drugs Market Analysis and Forecast By Treatment
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By Treatment
      8.1.2 Basis Point Share (BPS) Analysis By Treatment
      8.1.3 Absolute $ Opportunity Assessment By Treatment
   8.2 Radiation Injury Drugs Market Size Forecast By Treatment
      8.2.1 Treatment For Radiation Sickness
      8.2.2 Treatment For Internal Contamination
      8.2.3 Others
   8.3 Market Attractiveness Analysis By Treatment
Chapter 9 Global Radiation Injury Drugs Market Analysis and Forecast By Route of Administration
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities By Route of Administration
      9.1.2 Basis Point Share (BPS) Analysis By Route of Administration
      9.1.3 Absolute $ Opportunity Assessment By Route of Administration
   9.2 Radiation Injury Drugs Market Size Forecast By Route of Administration
      9.2.1 Oral
      9.2.2 Parenteral
   9.3 Market Attractiveness Analysis By Route of Administration
Chapter 10 Global Radiation Injury Drugs Market Analysis and Forecast By Applications
   10.1 Introduction
      10.1.1 Key Market Trends & Growth Opportunities By Applications
      10.1.2 Basis Point Share (BPS) Analysis By Applications
      10.1.3 Absolute $ Opportunity Assessment By Applications
   10.2 Radiation Injury Drugs Market Size Forecast By Applications
      10.2.1 Ambulatory Surgery Centers (ASCs)
      10.2.2 Hospitals
      10.2.3 Research Institutes
      10.2.4 Others
   10.3 Market Attractiveness Analysis By Application
Chapter 11 Global Radiation Injury Drugs Market Analysis and Forecast by Region
   11.1 Introduction
      11.1.1 Key Market Trends & Growth Opportunities by Region
      11.1.2 Basis Point Share (BPS) Analysis by Region
      11.1.3 Absolute $ Opportunity Assessment by Region
   11.2 Radiation Injury Drugs Market Size Forecast by Region
      11.2.1 North America
      11.2.2 Europe
      11.2.3 Asia Pacific
      11.2.4 Latin America
      11.2.5 Middle East & Africa (MEA)
   11.3 Market Attractiveness Analysis by Region
Chapter 12 Coronavirus Disease (COVID-19) Impact
   12.1 Introduction
   12.2 Current & Future Impact Analysis
   12.3 Economic Impact Analysis
   12.4 Government Policies
   12.5 Investment Scenario
Chapter 13 North America Radiation Injury Drugs Analysis and Forecast
   13.1 Introduction
   13.2 North America Radiation Injury Drugs Market Size Forecast by Country
      13.2.1 U.S.
      13.2.2 Canada
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 North America Radiation Injury Drugs Market Size Forecast By Exposure
      13.6.1 Internal Exposure
      13.6.2 External Exposure
   13.7 Basis Point Share (BPS) Analysis By Exposure
   13.8 Absolute $ Opportunity Assessment By Exposure
   13.9 Market Attractiveness Analysis By Exposure
   13.10 North America Radiation Injury Drugs Market Size Forecast By Source
      13.10.1 Background Radiation
      13.10.2 Man-made Radiation
   13.11 Basis Point Share (BPS) Analysis By Source
   13.12 Absolute $ Opportunity Assessment By Source
   13.13 Market Attractiveness Analysis By Source
   13.14 North America Radiation Injury Drugs Market Size Forecast By Diagnosis
      13.14.1 Lymphocytes Count
      13.14.2 Geiger-Muller Counter
      13.14.3 Blood Test And dosimeter
   13.15 Basis Point Share (BPS) Analysis By Diagnosis
   13.16 Absolute $ Opportunity Assessment By Diagnosis
   13.17 Market Attractiveness Analysis By Diagnosis
   13.18 North America Radiation Injury Drugs Market Size Forecast By Treatment
      13.18.1 Treatment For Radiation Sickness
      13.18.2 Treatment For Internal Contamination
      13.18.3 Others
   13.19 Basis Point Share (BPS) Analysis By Treatment
   13.20 Absolute $ Opportunity Assessment By Treatment
   13.21 Market Attractiveness Analysis By Treatment
   13.22 North America Radiation Injury Drugs Market Size Forecast By Route of Administration
      13.22.1 Oral
      13.22.2 Parenteral
   13.23 Basis Point Share (BPS) Analysis By Route of Administration
   13.24 Absolute $ Opportunity Assessment By Route of Administration
   13.25 Market Attractiveness Analysis By Route of Administration
   13.26 North America Radiation Injury Drugs Market Size Forecast By Applications
      13.26.1 Ambulatory Surgery Centers (ASCs)
      13.26.2 Hospitals
      13.26.3 Research Institutes
      13.26.4 Others
   13.27 Basis Point Share (BPS) Analysis By Applications
   13.28 Absolute $ Opportunity Assessment By Applications
   13.29 Market Attractiveness Analysis By Applications
Chapter 14 Europe Radiation Injury Drugs Analysis and Forecast
   14.1 Introduction
   14.2 Europe Radiation Injury Drugs Market Size Forecast by Country
      14.2.1 Germany
      14.2.2 France
      14.2.3 Italy
      14.2.4 U.K.
      14.2.5 Spain
      14.2.6 Russia
      14.2.7 Rest of Europe
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Europe Radiation Injury Drugs Market Size Forecast By Exposure
      14.6.1 Internal Exposure
      14.6.2 External Exposure
   14.7 Basis Point Share (BPS) Analysis By Exposure
   14.8 Absolute $ Opportunity Assessment By Exposure
   14.9 Market Attractiveness Analysis By Exposure
   14.10 Europe Radiation Injury Drugs Market Size Forecast By Source
      14.10.1 Background Radiation
      14.10.2 Man-made Radiation
   14.11 Basis Point Share (BPS) Analysis By Source
   14.12 Absolute $ Opportunity Assessment By Source
   14.13 Market Attractiveness Analysis By Source
   14.14 Europe Radiation Injury Drugs Market Size Forecast By Diagnosis
      14.14.1 Lymphocytes Count
      14.14.2 Geiger-Muller Counter
      14.14.3 Blood Test And dosimeter
   14.15 Basis Point Share (BPS) Analysis By Diagnosis
   14.16 Absolute $ Opportunity Assessment By Diagnosis
   14.17 Market Attractiveness Analysis By Diagnosis
   14.18 Europe Radiation Injury Drugs Market Size Forecast By Treatment
      14.18.1 Treatment For Radiation Sickness
      14.18.2 Treatment For Internal Contamination
      14.18.3 Others
   14.19 Basis Point Share (BPS) Analysis By Treatment
   14.20 Absolute $ Opportunity Assessment By Treatment
   14.21 Market Attractiveness Analysis By Treatment
   14.22 Europe Radiation Injury Drugs Market Size Forecast By Route of Administration
      14.22.1 Oral
      14.22.2 Parenteral
   14.23 Basis Point Share (BPS) Analysis By Route of Administration
   14.24 Absolute $ Opportunity Assessment By Route of Administration
   14.25 Market Attractiveness Analysis By Route of Administration
   14.26 Europe Radiation Injury Drugs Market Size Forecast By Applications
      14.26.1 Ambulatory Surgery Centers (ASCs)
      14.26.2 Hospitals
      14.26.3 Research Institutes
      14.26.4 Others
   14.27 Basis Point Share (BPS) Analysis By Applications
   14.28 Absolute $ Opportunity Assessment By Applications
   14.29 Market Attractiveness Analysis By Applications
Chapter 15 Asia Pacific Radiation Injury Drugs Analysis and Forecast
   15.1 Introduction
   15.2 Asia Pacific Radiation Injury Drugs Market Size Forecast by Country
      15.2.1 China
      15.2.2 Japan
      15.2.3 South Korea
      15.2.4 India
      15.2.5 Australia
      15.2.6 South East Asia (SEA)
      15.2.7 Rest of Asia Pacific (APAC)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Asia Pacific Radiation Injury Drugs Market Size Forecast By Exposure
      15.6.1 Internal Exposure
      15.6.2 External Exposure
   15.7 Basis Point Share (BPS) Analysis By Exposure
   15.8 Absolute $ Opportunity Assessment By Exposure
   15.9 Market Attractiveness Analysis By Exposure
   15.10 Asia Pacific Radiation Injury Drugs Market Size Forecast By Source
      15.10.1 Background Radiation
      15.10.2 Man-made Radiation
   15.11 Basis Point Share (BPS) Analysis By Source
   15.12 Absolute $ Opportunity Assessment By Source
   15.13 Market Attractiveness Analysis By Source
   15.14 Asia Pacific Radiation Injury Drugs Market Size Forecast By Diagnosis
      15.14.1 Lymphocytes Count
      15.14.2 Geiger-Muller Counter
      15.14.3 Blood Test And dosimeter
   15.15 Basis Point Share (BPS) Analysis By Diagnosis
15.16 Absolute $ Opportunity Assessment By Diagnosis
   15.17 Market Attractiveness Analysis By Diagnosis
   15.18 Asia Pacific Radiation Injury Drugs Market Size Forecast By Treatment
      15.18.1 Treatment For Radiation Sickness
      15.18.2 Treatment For Internal Contamination
      15.18.3 Others
   15.19 Basis Point Share (BPS) Analysis By Treatment
   15.20 Absolute $ Opportunity Assessment By Treatment
   15.21 Market Attractiveness Analysis By Treatment
   15.22 Asia Pacific Radiation Injury Drugs Market Size Forecast By Route of Administration
      15.22.1 Oral
      15.22.2 Parenteral
   15.23 Basis Point Share (BPS) Analysis By Route of Administration
   15.24 Absolute $ Opportunity Assessment By Route of Administration
   15.25 Market Attractiveness Analysis By Route of Administration
   15.26 Asia Pacific Radiation Injury Drugs Market Size Forecast By Applications
      15.26.1 Ambulatory Surgery Centers (ASCs)
      15.26.2 Hospitals
      15.26.3 Research Institutes
      15.26.4 Others
   15.27 Basis Point Share (BPS) Analysis By Applications
   15.28 Absolute $ Opportunity Assessment By Applications
   15.29 Market Attractiveness Analysis By Applications
Chapter 16 Latin America Radiation Injury Drugs Analysis and Forecast
   16.1 Introduction
   16.2 Latin America Radiation Injury Drugs Market Size Forecast by Country
      16.2.1 Brazil
      16.2.2 Mexico
      16.2.3 Rest of Latin America (LATAM)
   16.3 Basis Point Share (BPS) Analysis by Country
   16.4 Absolute $ Opportunity Assessment by Country
   16.5 Market Attractiveness Analysis by Country
   16.6 Latin America Radiation Injury Drugs Market Size Forecast By Exposure
      16.6.1 Internal Exposure
      16.6.2 External Exposure
   16.7 Basis Point Share (BPS) Analysis By Exposure
   16.8 Absolute $ Opportunity Assessment By Exposure
   16.9 Market Attractiveness Analysis By Exposure
   16.10 Latin America Radiation Injury Drugs Market Size Forecast By Source
      16.10.1 Background Radiation
      16.10.2 Man-made Radiation
   16.11 Basis Point Share (BPS) Analysis By Source
   16.12 Absolute $ Opportunity Assessment By Source
   16.13 Market Attractiveness Analysis By Source
   16.14 Latin America Radiation Injury Drugs Market Size Forecast By Diagnosis
      16.14.1 Lymphocytes Count
      16.14.2 Geiger-Muller Counter
      16.14.3 Blood Test And dosimeter
   16.15 Basis Point Share (BPS) Analysis By Diagnosis
   16.16 Absolute $ Opportunity Assessment By Diagnosis
   16.17 Market Attractiveness Analysis By Diagnosis
   16.18 Latin America Radiation Injury Drugs Market Size Forecast By Treatment
      16.18.1 Treatment For Radiation Sickness
      16.18.2 Treatment For Internal Contamination
      16.18.3 Others
   16.19 Basis Point Share (BPS) Analysis By Treatment
   16.20 Absolute $ Opportunity Assessment By Treatment
   16.21 Market Attractiveness Analysis By Treatment
   16.22 Latin America Radiation Injury Drugs Market Size Forecast By Route of Administration
      16.22.1 Oral
      16.22.2 Parenteral
   16.23 Basis Point Share (BPS) Analysis By Route of Administration
   16.24 Absolute $ Opportunity Assessment By Route of Administration
   16.25 Market Attractiveness Analysis By Route of Administration
   16.26 Latin America Radiation Injury Drugs Market Size Forecast By Applications
      16.26.1 Ambulatory Surgery Centers (ASCs)
      16.26.2 Hospitals
      16.26.3 Research Institutes
      16.26.4 Others
   16.27 Basis Point Share (BPS) Analysis By Applications
   16.28 Absolute $ Opportunity Assessment By Applications
   16.29 Market Attractiveness Analysis By Applications
Chapter 17 Middle East & Africa (MEA) Radiation Injury Drugs Analysis and Forecast
   17.1 Introduction
   17.2 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast by Country
      17.2.1 Saudi Arabia
      17.2.2 South Africa
      17.2.3 UAE
      17.2.4 Rest of Middle East & Africa (MEA)
   17.3 Basis Point Share (BPS) Analysis by Country
   17.4 Absolute $ Opportunity Assessment by Country
   17.5 Market Attractiveness Analysis by Country
   17.6 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Exposure
      17.6.1 Internal Exposure
      17.6.2 External Exposure
   17.7 Basis Point Share (BPS) Analysis By Exposure
   17.8 Absolute $ Opportunity Assessment By Exposure
   17.9 Market Attractiveness Analysis By Exposure
   17.10 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Source
      17.10.1 Background Radiation
      17.10.2 Man-made Radiation
   17.11 Basis Point Share (BPS) Analysis By Source
   17.12 Absolute $ Opportunity Assessment By Source
   17.13 Market Attractiveness Analysis By Source
   17.14 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Diagnosis
      17.14.1 Lymphocytes Count
      17.14.2 Geiger-Muller Counter
      17.14.3 Blood Test And dosimeter
   17.15 Basis Point Share (BPS) Analysis By Diagnosis
   17.16 Absolute $ Opportunity Assessment By Diagnosis
   17.17 Market Attractiveness Analysis By Diagnosis
   17.18 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Treatment
      17.18.1 Treatment For Radiation Sickness
      17.18.2 Treatment For Internal Contamination
      17.18.3 Others
   17.19 Basis Point Share (BPS) Analysis By Treatment
   17.20 Absolute $ Opportunity Assessment By Treatment
   17.21 Market Attractiveness Analysis By Treatment
   17.22 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Route of Administration
      17.22.1 Oral
      17.22.2 Parenteral
   17.23 Basis Point Share (BPS) Analysis By Route of Administration
   17.24 Absolute $ Opportunity Assessment By Route of Administration
   17.25 Market Attractiveness Analysis By Route of Administration
   17.26 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Applications
      17.26.1 Ambulatory Surgery Centers (ASCs)
      17.26.2 Hospitals
      17.26.3 Research Institutes
      17.26.4 Others
   17.27 Basis Point Share (BPS) Analysis By Applications
   17.28 Absolute $ Opportunity Assessment By Applications
   17.29 Market Attractiveness Analysis By Applications
Chapter 18 Competition Landscape
   18.1 Radiation Injury Drugs Market: Competitive Dashboard
   18.2 Global Radiation Injury Drugs Market: Market Share Analysis, 2020
   18.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      18.3.1 Eli Lilly and Company
  18.3.2 Teva Pharmaceutical
      18.3.3 Amgen Inc
18.3.4 La Jolla Pharmaceutical Co
      18.3.5 Novartis
  18.3.6 Johnson & Johnson
      18.3.7 Heyl Chemisch-pharmazeutische Fabrik

Methodology

Purchase Premium Report

Buy Now

Request For Sample

Request For Customization

Enquiry Before Buying

Speak With Analyst

Customize This Report

Ask for Research To Be Focused On Specific Regions or Segments
Receive Data As Per Your Format and Definition
Companies Profiled based on Your Requirements
Breaking Down Competitive Landscape as per Your Requirements
Any Level of Customization

Our Clients

Client Testinomials

We needed a highly accurate and precise report, which Growth Market Reports delivered promptly. The company compiled information from a wide array of reliable agencies and sourcess.It is extremely satisfactory to be working with you.
Strategy Head of Major Tech Company

We were very pleased to contact Growth Market Reports as they tailored reports precisely as per our requirements. As we are dealing with the aerospace and defense industry, we need reports of high accuracy and substantial quality.
Major Player in Defense Industry

Extremely delighted to have a well-crafted report on “Global Packaging Solutions Market Research Report” from your team. Thank you for providing me with all our requirements and for incorporating our suggestions.
CMO of Leading Packaging Company from USA

I had a good experience working with Growth Market Reports as they were very open to all constructive changes in the report. I found that the report had its charm embedded with ample of data.
Founder and Managing Partner of Major Korean Company

Our company has been working with Growth Market Reports for some years now and we are very happy with the quality of the reports provided by the company.I, on behalf of my organization, would like to thank you for offering professional reports.
Global Consulting Firm

Quick Contact

+1 909 414 1393

sales@growthmarketreports.com

Growth Market Report

Certified By

FAQ Section

Some frequently asked questions about this report!

1. Who are the major players operating in the market?

Major Manufactures include Eli Lilly and Company, Teva Pharmaceutical, Amgen Inc, La Jolla Pharmaceutical Co, Novartis, Johnson & Johnson, Heyl Chemisch-pharmazeutische Fabrik.

2. Which is the base year calculated in the global radiation injury drugs market report and what is analysis period?

The base year considered for the global radiation injury drugs market report is 2020. The complete analysis period is 2018 to 2028, wherein, 2018 & 2019 are the historic years, and the forecast is provided from 2021 to 2028.

3. What is the impact of COVID-19 on the overall market during year 2019 -2020?

The market is expected to witness sluggish growth with slow increase in terms of demand during 2019-2020 owing to the negative impact of COVID-19 pandemic on the global radiation injury drugs market.

4. What are the key industries driving the market growth?

Ambulatory Surgery Centers (ASCs), Hospitals, Research Institutes, and Long-Term Care Centers are expected to expand at a substantial rate during the forecast period in globe.

5. What are the factors driving the growth of Global Radiation Injury Drugs Market?

Rising prevalence of cancer patients globally, as well as their preference for radiation therapy, are driving the radiation injury drugs market. Investments in R&D sector of radiation injury drugs are increasing globally, which is also estimated to drive the market.